NO20052923L - Fusjonerte bicykliske nitrogeninneholdende heteroringer - Google Patents

Fusjonerte bicykliske nitrogeninneholdende heteroringer

Info

Publication number
NO20052923L
NO20052923L NO20052923A NO20052923A NO20052923L NO 20052923 L NO20052923 L NO 20052923L NO 20052923 A NO20052923 A NO 20052923A NO 20052923 A NO20052923 A NO 20052923A NO 20052923 L NO20052923 L NO 20052923L
Authority
NO
Norway
Prior art keywords
fused bicyclic
containing heterocycles
bicyclic nitrogen
compounds
metabolic
Prior art date
Application number
NO20052923A
Other languages
English (en)
Other versions
NO20052923D0 (no
Inventor
Noboru Furukawa
Takashi Inaba
Masahiro Tanaka
Atsuhito Yoshida
Steven M Rubenstein
Brian M Fox
Xiaolin Hao
Kiyosei Ilo
Simon M Jackson
Frank Kayser
Marc Lebella
Kexue Li
Takuya Matsui
Dustin Mcminn
Nobuya Ogawa
Shoichi Sagawa
Kazuyuki Sugimoto
Masahiro Suzuki
Guosen Ye
Jian Zhang
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20052923D0 publication Critical patent/NO20052923D0/no
Publication of NO20052923L publication Critical patent/NO20052923L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives forbindelser, farmasøytiske preparater og metoder som er brukbar ved terapi eller prevensjon av metabolske og celleproliferative sykdommer eller tilstander. Særlig tilveiebringer oppfinnelsen forbindelser som modulerer aktiviteten av proteiner involvert i lipidmetabolisme og celleproliferering.
NO20052923A 2002-11-22 2005-06-15 Fusjonerte bicykliske nitrogeninneholdende heteroringer NO20052923L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42860002P 2002-11-22 2002-11-22
PCT/US2003/037574 WO2004047755A2 (en) 2002-11-22 2003-11-21 Fused bicyclic nitrogen-containing heterocycles

Publications (2)

Publication Number Publication Date
NO20052923D0 NO20052923D0 (no) 2005-06-15
NO20052923L true NO20052923L (no) 2005-08-18

Family

ID=32393428

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052923A NO20052923L (no) 2002-11-22 2005-06-15 Fusjonerte bicykliske nitrogeninneholdende heteroringer

Country Status (15)

Country Link
US (2) US7244727B2 (no)
EP (1) EP1562956A4 (no)
JP (1) JP3988830B2 (no)
KR (1) KR100772297B1 (no)
CN (1) CN1753897A (no)
AU (1) AU2003293006A1 (no)
BR (1) BR0315688A (no)
CA (1) CA2514473C (no)
IL (1) IL168497A0 (no)
MX (1) MXPA05005425A (no)
NO (1) NO20052923L (no)
NZ (1) NZ539952A (no)
RU (1) RU2342388C2 (no)
WO (1) WO2004047755A2 (no)
ZA (1) ZA200503823B (no)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7244727B2 (en) * 2002-11-22 2007-07-17 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1718309A2 (en) * 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
JP2008516978A (ja) * 2004-10-15 2008-05-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用
EP2332527A3 (en) * 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
KR20070087096A (ko) 2004-12-14 2007-08-27 아스트라제네카 아베 Ｄｇａｔ 억제제로서의 옥사디아졸 유도체
WO2006082010A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Inhibitors of diacylglycerol acyltransferase (dgat)
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
ES2331535T3 (es) 2005-05-10 2010-01-07 Via Pharmaceuticals, Inc. Inhibidores de diacilglicerol aciltransferasa.
AU2006247695B2 (en) * 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006258917A1 (en) * 2005-06-11 2006-12-21 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP5076091B2 (ja) 2005-11-28 2012-11-21 マドリガル・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼ（ｄｇａｔ）のインヒビター
WO2007063839A1 (ja) * 2005-11-30 2007-06-07 Shionogi & Co., Ltd. シクロヘキサン誘導体
WO2007071966A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
CA2637717A1 (en) * 2006-01-20 2007-08-02 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
JPWO2007114213A1 (ja) * 2006-03-30 2009-08-13 旭化成ファーマ株式会社 置換二環式環状誘導体及びその用途
EP2402320A1 (en) * 2006-03-31 2012-01-04 Novartis AG Anorectic agents
NZ572586A (en) 2006-05-30 2011-03-31 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
JP2009538891A (ja) 2006-05-30 2009-11-12 アストラゼネカ アクチボラグ Ｄｇａｔ１阻害剤としての１，３，４−オキサジアゾール誘導体
NZ573576A (en) 2006-06-08 2011-01-28 Astrazeneca Ab Benzimidazoles and their use for the treatment of diabetes
GB0611506D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
ES2373160T3 (es) 2006-09-19 2012-02-01 Daiichi Sankyo Company, Limited Derivado de pirazolopirimidina.
CN101636155A (zh) 2006-11-29 2010-01-27 艾博特公司 二酰甘油o-酰基转移酶1型酶的抑制剂
RU2009126418A (ru) * 2006-12-11 2011-01-20 Новартис АГ (CH) Способ профилактики или лечения ишемии миокарда
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
WO2008099221A1 (en) * 2007-02-15 2008-08-21 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
JP5349462B2 (ja) * 2007-05-16 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション スピロインダロン
US20090099201A1 (en) * 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
US8115011B2 (en) * 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) * 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) * 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
CN101678019B (zh) 2007-06-08 2016-03-30 詹森药业有限公司 哌啶/哌嗪衍生物
CA2687918C (en) * 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
PE20091682A1 (es) 2007-12-20 2009-12-04 Astrazeneca Ab Compuestos de carbamoilo como inhibidores de dgat1 190
WO2009126861A2 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolopyridine compounds useful as dgat1 inhibitors
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
CA2725933C (en) 2008-06-05 2018-01-16 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8211884B2 (en) * 2008-08-06 2012-07-03 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP3025727A1 (en) * 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
AU2009322774A1 (en) * 2008-12-03 2011-06-30 Via Pharmaceuticals, Inc Inhibitors of diacylglycerol acyltransferase
JP2012512252A (ja) * 2008-12-17 2012-05-31 ブイアイエイ・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼの阻害剤
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
TW201040174A (en) 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
TW201040175A (en) 2009-02-04 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
MX2011008677A (es) 2009-02-25 2011-09-08 Daiichi Sankyo Co Ltd Derivados de pirazolopirimidina triciclicos.
KR101841003B1 (ko) 2009-03-18 2018-03-22 리스버로직스 코퍼레이션 신규한 소염제
AU2010226826A1 (en) * 2009-03-18 2011-10-13 Merck Sharp & Dohme Corp. Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
EP3366686B9 (en) 2009-03-20 2021-08-04 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
AU2010261499A1 (en) 2009-06-19 2012-01-12 Astrazeneca Ab Pyrazine carboxamides as inhibitors of DGAT1
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
KR20120092629A (ko) 2009-10-09 2012-08-21 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
CN102834099B (zh) 2010-03-30 2015-05-27 诺华有限公司 Dgat1抑制剂的用途
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
KR20130099006A (ko) 2010-08-23 2013-09-05 다이이찌 산쿄 가부시키가이샤 3 고리성 피라졸로피리미딘 유도체의 프리체 결정
TW201213333A (en) 2010-08-23 2012-04-01 Daiichi Sankyo Co Ltd Crystal forms of tricyclic pyrazolopyrimidine derivative
KR20130013199A (ko) 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
SG11201402405QA (en) 2011-11-18 2014-09-26 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
FR2986232B1 (fr) * 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
WO2013157792A1 (en) * 2012-04-17 2013-10-24 Hanmi Pharm. Co., Ltd. Bicyclic heteroaryl derivative and pharmaceutical composition comprising same
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
US9550793B2 (en) 2012-10-03 2017-01-24 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014081995A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
EP2970282B1 (en) * 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
ES2635560T3 (es) 2013-07-08 2017-10-04 Incyte Holdings Corporation Heterociclos tricíclicos como inhibidores de la proteína NET
WO2015066697A1 (en) * 2013-11-04 2015-05-07 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
PL3674302T3 (pl) 2014-04-23 2023-07-24 Incyte Holdings Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
CN105218561B (zh) * 2014-06-25 2018-10-30 上海艾力斯医药科技有限公司 稠合嘧啶环衍生物、其制备方法及应用
TWI712603B (zh) 2014-09-15 2020-12-11 美商英塞特公司 作為ｂｅｔ蛋白抑制劑之三環雜環
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
CN104496795B (zh) * 2014-12-12 2016-09-14 重庆博腾制药科技股份有限公司 一种dgat-1抑制剂中间体的制备方法
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US11136333B2 (en) 2016-05-23 2021-10-05 The Texas A&M University System Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use
HRP20230466T1 (hr) 2016-06-20 2023-07-21 Incyte Corporation Kristalni čvrsti oblici bet inhibitora
WO2018039518A1 (en) * 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
MX2020008984A (es) * 2018-02-28 2020-12-09 Dart Neuroscience Llc Compuestos de ciclohexilo sustituido como inhibidores de nop.
MY205335A (en) 2018-03-16 2024-10-16 Anji Pharmaceuticals Inc Compositions and methods for treating severe constipation
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH05213985A (ja) 1992-02-10 1993-08-24 Mitsubishi Kasei Corp ピロールカルボン酸コエンザイムａ誘導体
US6069143A (en) * 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
JP2001097979A (ja) * 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
JP2002284741A (ja) * 2001-03-23 2002-10-03 Kitasato Inst:The ローズリピン誘導体
HUP0401963A3 (en) 2001-08-09 2006-01-30 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
KR100460438B1 (ko) 2001-12-01 2004-12-08 한국생명공학연구원 아실 코에이:디아실글리세롤 아실트랜스퍼라제활성저해제인 신규 폴리아세틸렌계 화합물 및 이의 제조방법
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
US7244727B2 (en) * 2002-11-22 2007-07-17 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles

Also Published As

Publication number Publication date
CA2514473C (en) 2008-05-27
AU2003293006A1 (en) 2004-06-18
EP1562956A2 (en) 2005-08-17
NO20052923D0 (no) 2005-06-15
US20070244096A1 (en) 2007-10-18
CN1753897A (zh) 2006-03-29
RU2342388C2 (ru) 2008-12-27
EP1562956A4 (en) 2007-10-10
MXPA05005425A (es) 2005-11-23
CA2514473A1 (en) 2004-06-10
WO2004047755A2 (en) 2004-06-10
ZA200503823B (en) 2006-02-22
WO2004047755A3 (en) 2004-11-25
KR20050090986A (ko) 2005-09-14
IL168497A0 (en) 2009-02-11
JP3988830B2 (ja) 2007-10-10
JP2006509764A (ja) 2006-03-23
US20040209871A1 (en) 2004-10-21
BR0315688A (pt) 2005-09-06
NZ539952A (en) 2008-05-30
KR100772297B1 (ko) 2007-11-02
US7244727B2 (en) 2007-07-17
RU2005119646A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EP1435946B8 (en) Linked biaryl compounds
WO2002041843A3 (en) Antiinflammation agents
ATE511840T1 (de) Imidazolderivate als entzündungshemmende mittel
WO2005013907A3 (en) Pyrrolo[1,2-b]pyridazine derivatives
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
MX365890B (es) Moduladores de transportadores con casete de unión con atp.
NO20070091L (no) Sukkerbelegg og fremgangsmate for dette
NO20070782L (no) Tetrapeptidanaloger.
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
NO20044261L (no) Indazoler substituerte med en anticanceros aktivitet
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
WO2003048152A3 (en) Inflammation modulators
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application